TSXV:CLAS.H - Post Discussion
Post by
Red~One on Aug 23, 2022 3:05pm
ultra-high concentration nitric oxide therapy
Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy
- Beyond Air ( NASDAQ: XAIR ) unit Beyond Cancer said on Tuesday the first patient had been treated in a Phase 1 study to assess the safety and immune biomarkers of ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors.
- The company expects initial clinical data from the trial in early 2023.
- The study will evaluate the maximum tolerated dose, safety and immune biomarkers of UNO injection into solid tumors that are not amenable to or have failed standard treatment.
- The primary endpoints of the early-stage study are the incidence and characteristics of adverse events, serious adverse events, dose-limiting toxicities, and changes in safety parameters.
- ( XAIR ) rose ~4% premarket.
For further details see:
Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy Source: SeekingAlpha (Aug 23, 2022 09:12:20 EDT)
News by QuoteMedia
www.quotemedia.com
Be the first to comment on this post